Current Research Studies

COPPER HISTIDINATE TREATMENT FOR MENKES DISEASE

CYP-001

Condition(s): Other
Phase: N/A
Clinicaltrials.gov ID: NCT04074512

What is the goal of the study?

This study investigates the clinical effects and safety of subcutaneous Copper Histidinate treatment for patients diagnosed with Menkes disease and previously treated at NICHD under protocol 09-CH-0059 and newly diagnosed Menkes disease patients.

Who can participate in the study?

Please contact the study team listed below to learn more.

Study Team:

PI (Study Doctor): Monica Penon Portmann
Study Team Member: Hayden Vreugdenhil, Hayden.Vreugdenhil@seattlechildrens.org

Seattle Children’s complies with applicable federal and other civil rights laws and does not discriminate, exclude people or treat them differently based on race, color, religion (creed), sex, gender identity or expression, sexual orientation, national origin (ancestry), age, disability, or any other status protected by applicable federal, state or local law. Financial assistance for medically necessary services is based on family income and hospital resources and is provided to children under age 21 whose primary residence is in Washington, Alaska, Montana or Idaho.